Clinician compliance to recommendations regarding the risk of suicidality with selective serotonin reuptake inhibitors in the treatment of children and adolescents

Johanne Østerby Sørensen1 · Annette Rasmussen1 · Troels Roesbjerg2 · Anne Katrine Pagsberg1

Received: 12 January 2018 / Accepted: 31 October 2019 / Published online: 7 November 2019
© The Author(s) 2019

Abstract
Meta-analyses of randomized-controlled trials have established a heightened risk of suicidality for children and adolescents treated with selective serotonin reuptake inhibitors (SSRIs). The present study examined to what extent daily clinical practice complied with specific recommendations regarding the risk of suicidality when treating children and adolescents with SSRIs. All in- and outpatients aged 0–17 years at the Child and Adolescent Mental Health Services, Capital Region of Denmark with a prescription for SSRI on January 1st, 2016 were identified. Data were obtained for n = 365 patients regarding the level of clinician compliance to deliver pre-consent information about adverse effects, monitor for suicidality, and provide non-pharmacological interventions. 81.7% (n = 298) of patients received pre-consent information about adverse effects. 67.7% (n = 247) were monitored for suicidality within 6 weeks after SSRI initiation. Children (0–13 years) were less likely to be monitored for suicidality compared to adolescents (14–17 years) (49.6% vs. 77.5%, p < 0.001). Patients with depression as indication for SSRI treatment were more likely to be monitored for suicidality than patients with other indications (OR = 3.4, p = 0.002) and more likely to receive information specifically about suicidality (34.7% vs. 19.7%, p = 0.002). Respectively, 89.3% (n = 326) and 93.4% (n = 341) of all SSRI-treated patients were treated with non-pharmacological interventions prior to and in parallel with SSRI treatment. For the majority of cases, treatment of children and adolescents with SSRI complied with recommendations from clinical guidelines. However, patients of younger age and/or with indications for SSRIs other than depression were less likely to be managed according to recommendations.

Keywords Selective serotonin reuptake inhibitors · Children and adolescents · Adverse effects · Suicidality · Guideline compliance

Introduction
In recent years, the use of antidepressant drugs among children and adolescents has increased in western countries [1, 2]. Several meta-analyses of data from randomized-controlled trials (RCT’s) have found an increased risk of suicidality for children and adolescents treated with antidepressants [3–7]. In 2004, The American Food and Drug Administration (FDA) directed that the labelling of all antidepressants should include a boxed warning of an increased risk of suicidality for children and adolescents [8], and in 2007, this was expanded to include young adults (ages 18–24 years) [9]. In 2005, The European Medicines Agency issued a warning about the use of antidepressants for children and adolescents [10]. Likewise, clinical guidelines covering the use of antidepressants for children and adolescents have taken the risk of suicidality into consideration [11–16]. The guidelines generally recommend non-pharmacological interventions as first-line treatment for children and adolescents with depression, anxiety, and OCD, and if antidepressants are necessary, they should be used as a supplement to boost non-pharmacological interventions. Most guidelines recommend careful monitoring for suicidality as an adverse effect after initiation of antidepressant treatment. However,
the guidelines differ regarding what time period and for what diagnostic indications for antidepressants, the risk of suicidality should be considered. These differences reflect that for the indication of major depressive disorder, suicidality as an adverse effect has been well described, but the risk of suicidality is not as clearly established when antidepressants are given on other diagnostic indications [6]. Neither has the present literature fully described in what time period during treatment, antidepressant-related suicidality might occur [17–19]. The guidelines have no specific recommendations for monitoring and information about adverse effects during dosage changes. In many of the RCTs, patients with high risk of suicide and many co-morbid disorders were excluded [3, 20], thus complicating extrapolation to a clinical population, why observational studies are necessary to describe a more representative population and reflect clinical practice. The present study aims to determine whether the antidepressant or in particular SSRI treatment of children and adolescents in daily clinical practice complies with specific national recommendations regarding suicidality from The Danish Health Authority. The hypothesis of the study is that SSRI treatment of children and adolescents is in concordance with clinical recommendations, thus:

1. Clinicians give information about suicidality as an adverse effect of SSRIs to patients and their parents.
2. Patients are monitored for suicidality during the first 6 weeks of treatment (or longer if needed).
3. (a) Non-pharmacological interventions are first-line treatment before SSRI treatment is initiated.
   (b) SSRIs are used as a supplement to boost non-pharmacological interventions.

The hypothesis is based on recommendations from The Danish Health Authority clinical guidelines issued in 2013. Previous guidelines were issued by the Danish Health Authority in 2012 and 2007. The guidelines issued in 2012 and 2007 were similar in terms of recommendation of non-pharmacological interventions before and in parallel with SSRI treatment and the management of SSRI-related suicidality. However, the guidelines from 2007 were less explicit on the management of suicidality as an adverse effect in comparison to the guidelines from 2012 and 2013 [21].

Methods

Design

A cross-sectional study with follow-back and follow-up was conducted on January 1st 2016 based on data extracted from electronic prescription software (PLISS) used for all prescriptions at Child and Adolescent Mental Health Services (CAMHS), Capital Region, Denmark. All patients have a unique id number which was used to extract data from the digitalized medical record (OPUS) and the electronic medicine monitoring system (EPM).

Study population

Inclusion criteria

All in- or outpatients aged 0–17 years with a recorded prescription for an SSRI classified within ATC-group N06AB undergoing treatment at the CAMHS. CAMHS is a public mental health center which holds the main responsibility for the hospital-based treatment in the Capital Region of Denmark, encompassing 8752 unique in- and outpatients in 2015. The Capital Region is the most populous region of Denmark with a population of 359441 children (aged 0–17) in 2015 [22]. In Denmark, free health care is available to all citizens and financed via income taxes.

Exclusion criteria

Patients aged 18 years and above on the date of SSRI initiation and patients who were not undergoing SSRI treatment on January 1st 2016 according to the medical record were excluded. Cases where SSRI treatment was not initiated in CAMHS (i.e., SSRI treatment was initiated in a private child- and adolescent psychiatric practice, or another practitioner, not part of CAMHS) were excluded, because precise information about the initiation and management of medical treatment was not available in the CAMHS medical records. For the same reason, cases in which it was impossible to determine who initiated the SSRI treatment were excluded. Cases with another recorded prescription for SSRI prior to the SSRI which was prescribed on January 1st 2016 were excluded.

Case extraction

Patients with a prescription for an SSRI were identified by one researcher (TR) in June 2016. Two researchers (JØS and AR) searched the medical records and the medicine monitoring system for cases. For each case, the medical record was searched manually for relevant data from the first entry in the course of treatment that included SSRI prescription until the date of SSRI initiation (termed: the period prior to SSRI initiation), and from SSRI initiation date until 6 months after treatment initiation or until the patient was no longer a patient in CAMHS (termed: the period after SSRI initiation). The date of SSRI initiation ranged from year 2009 to 2015.
Data collection

For each patient, the following data were extracted:

1. Date of study entry and end of follow-up
2. Gender
3. Age on SSRI initiation date. Patients were grouped as children (aged 0–13 years) or adolescents (aged 14–17 years)
4. Patient status (in- or outpatient) on initiation date
5. Data on SSRI use: initiation date, type of drug, indication, initiation dose, maximum dose, and maintenance dose. Data on the date of dose changes were not available.
6. Medication status prior to, on the day of, and after SSRI initiation
7. Psychiatric diagnoses according to ICD-10 [23]. Since diagnoses could be changed during the study period, diagnoses from an entry immediately before or on the initiation date were extracted. Tentative diagnoses were included if a firm diagnosis was not yet established.
8. Suicidality (according to C-CASA) [24] prior to SSRI initiation.

Outcome variables

Pre-consent information about suicidality as an adverse effect of SSRI

The medical records were searched for entries regarding information from healthcare providers to the patient and/or their parent(s) concerning SSRI adverse effects on the date of or just prior to SSRI initiation. Information from the healthcare providers was registered as general information about adverse effects or specifically about suicidality as an adverse effect and to whom the information was given (parents, patient, or both) according to the medical record.

Monitoring for suicidality

In the period after SSRI initiation, the medical records were searched for screenings for suicidality conducted by the healthcare providers, suicidality assessments, or entries such as: “(no) suicidal ideations” or “(not) suicidal”. Monitoring face-to-face, by telephone and whether a side-effect rating scale was used to aid the evaluation of suicidality was registered. Phrases indicating a general assessment of adverse effects such as “no adverse effects” were not registered as valid monitoring for suicidality.

Non-pharmacological interventions

Non-pharmacological interventions were grouped in four main categories: psychotherapy, psychoeducation, supportive consultations, and reducing psychosocial stress factors. The categories were defined beforehand and adapted from The Danish Association for Child and Adolescent Psychiatry’s clinical guidelines for management and treatment of depression and OCD [25, 26]. A category termed “Other” was used if the non-pharmacological intervention did not match one of the main categories. Every recorded non-pharmacological intervention before and after SSRI initiation was registered in the period prior to SSRI initiation and in the period after SSRI initiation. If the same non-pharmacological intervention appeared more than once during the same period, the intervention was counted only once. If an intervention was delivered outside CAMHS, the intervention was registered separately. However, if the same specific intervention was also performed by the CAMHS healthcare providers, only the CAMHS intervention was registered.

Statistical analysis

Statistics were performed using IBM Corp, IBM SPSS Statistics for Windows Version 22. The Mann–Whitney U test was applied to test for significant age difference between males and females. The Pearson Chi-square test and Fisher’s exact test were used to evaluate the outcomes of treatment, monitoring and information about adverse effects according to age, gender, admission status, indication for SSRI, and suicidality prior to SSRI initiation. To analyse monitoring for suicidality according to age, gender, admission status, indication, and previous suicidality, a logistic regression analysis was performed with monitoring as the dependent variable and age group, gender, admission status, indication (depression or no depression), and previous suicidality as predictor variables.

Ethical aspects

The study was approved by the Danish Data Protection Agency (Journal no.: 2012-58-0004) and the Danish Patient Safety Authority (Journal no. 3-3013-1554/1 + 2/). Informed consent from patients and caretakers was not demanded. Approval from the Ethics Committee was not required according to Danish Law.

Results

In total, 5410 patients were associated with CAMHS on January 1st 2016. Out of 530 patients identified as SSRI users on initiation date, 365 patients were eligible for study.
inclusion. Figure 1 shows the inclusion of patients in the study and Table 1 summarizes patient characteristics. The majority (64.1%, n = 234) was female. Mean [SD] age was 14.5 years [2.04], ranging from 7.7 to 17.9 years, and was significantly higher for females than for males, (14.8 years [1.8] vs. 13.6 years [2], p < 0.001). More patients were adolescents (aged 14–17) compared to children (aged 0–13) (64.7%, n = 236 vs. 35.5%, n = 129, p < 0.001). Most patients were outpatients (77.8%, n = 284, p < 0.001). Sertraline was the most commonly used SSRI, (75.7%, n = 280), followed by fluoxetine (23.0%, n = 84). Only 0.3% (n = 1) of patients received Citalopram. The most common indication for SSRI treatment was depression (40.3%, n = 147), followed by anxiety, (29.6%, n = 108) and OCD (23.8%, n = 87). The majority (67.9%, n = 253) of patients had displayed suicidality prior to SSRI initiation. Adolescents more frequently displayed pre-SSRI suicidality than children (75.2%, n = 178 vs. 58.1% n = 75, p = 0.001) and females more frequently than males (75.2%, n = 176 vs. 58.8%, n = 77, p = 0.003) Fig. 2.

The date of SSRI initiation ranged from 14.04.2009 to 30.12.2015. 16.7% (N = 61) of patients started SSRI prior to the issue of the 2013 version of the guidelines from the Danish Health Authority.

**Information about suicidality as an adverse effect of SSRI**

Data on information given to the patient or parent(s) about suicidality as an adverse effect of SSRI is shown in Table 2. Most patients (81.7%, n = 298) had an entry in the medical record concerning information given from the healthcare providers to either the patient or their parent(s) about
| Table 1 | Characteristics of study population |
|---------|-----------------------------------|
|         | No. of patients (%) | Children (%) | Adolescents (%) | \( p^2 \) |
| Adolescents (14–17 yr) | 236 (64.7%) |  |
| Children (7–13 yr) | 129 (35.3%) |  |
| Gender |  |  |
| Female | 234 (64.1%) | 59 (45.7%) | 175 (25.8%) |  |
| Male | 131 (35.9%) | 70 (54.3%) | 61 (74.2%) | <0.001 |
| Patient status at SSRI initiation |  |  |
| Outpatient | 284 (77.8%) | 92 (71.3%) | 192 (81.4%) |  |
| Inpatient | 81 (22.2%) | 37 (28.7%) | 44 (18.6%) | 0.35 |
| Drug |  |  |
| Sertraline | 280 (76.7%) | 113 (87.6%) | 166 (70.3%) |  |
| Fluoxetine | 84 (23.0%) | 16 (12.4%) | 69 (29.2%) |  |
| Citalopram | 1 (0.3%) | 0 | 1 (0.4%) | 0.001 |
| Indication for SSRI |  |  |
| Depression | 147 (40.3%) | 31 (24.0%) | 116 (49.2%) |  |
| Anxiety | 108 (29.6%) | 39 (30.2%) | 69 (29.2%) |  |
| OCD | 87 (23.8%) | 51 (39.6%) | 36 (15.3%) |  |
| Depression and anxiety | 9 (2.5%) | 2 (1.6%) | 7 (3.0%) |  |
| Anxiety and OCD | 6 (1.6%) | 2 (1.6%) | 4 (1.7%) |  |
| Depression and OCD | 3 (0.8%) | 2 (1.6%) | 1 (0.4%) |  |
| Depression, anxiety, and OCD | 2 (0.5%) | 1 (0.8%) | 1 (0.4%) |  |
| “Nerve medicine” | 2 (0.5%) | 1 (0.8%) | 1 (0.4%) |  |
| PTSD and anxiety | 1 (0.3%) | 0 | 1 (0.4%) | <0.001 |
| Number of diagnoses |  |  |
| 1 | 104 (28.5%) | 37 (28.7%) | 67 (28.4%) |  |
| 2 | 142 (38.9%) | 46 (35.7%) | 96 (40.7%) |  |
| 3 | 90 (24.7%) | 34 (26.4%) | 56 (23.7%) |  |
| 4 | 24 (6.6%) | 10 (7.8%) | 14 (23.7%) |  |
| 5 | 5 (1.4%) | 2 (1.6%) | 3 (1.3%) |  |
| Previous suicidality | 253 (67.9%) | 75 (58.1%) | 178 (75.4%) | 0.001 |
| Other drugs at SSRI initiation |  |  |
| No | 218 (59.7%) | 69 (53.5%) | 149 (63.1%) |  |
| Yes | 147 (40.3%) | 60 (46.5%) | 87 (36.9%) | 0.075 |
| Other drugs at SSRI initiation |  |  |
| Melatonin | 93 (25.5%) |  |
| Quetiapine | 19 (5.2%) |  |
| Olanzapine | 16 (4.4%) |  |
| Chlorprothixene | 13 (3.6%) |  |
| Methylphenidate | 13 (3.6%) |  |
| Aripiprazole | 10 (2.7%) |  |
| Oxazepam | 9 (2.5%) |  |
| Risperidone | 9 (2.5%) |  |
| Atomoxetine | 4 (1.1%) |  |
| Lisdexamphetamine | 2 (0.5%) |  |
| Valproate | 2 (0.5%) |  |
| Lamotrigine | 2 (0.5%) |  |
| Clonidine | 1 (0.3%) |  |
SSRI adverse effects. In 21.4% ($n = 78$) of cases, the medical record had documentation that patients were specifically informed about suicidality as an adverse effect; 44.1% ($n = 161$) of patients were informed generally about adverse effects; and 34.5% ($n = 126$) of patients had no entry about adverse effect information. For the parents of the patients, 24.4% ($n = 89$) were specifically informed about suicidality as an adverse effect of SSRI; 52.1% ($n = 190$) were informed generally about adverse effects; and 23.6% ($n = 86$) of patients had no documentation for adverse effect information given to the parent(s). For 25.8% ($n = 94$) of the patients, the same diagnosis group, it was counted only once in this figure. Depression, pervasive developmental disorders, anxiety, and OCD were the most abundant diagnoses. The insert square depicts the types of depression.

**Table 1** (continued)

|                               | Range     | Mean (SD) | $p^b$ |
|-------------------------------|-----------|-----------|-------|
| Age, all (years)              | [7.7–17.9]| 14.5 (2.04)|       |
| Age, females (years)          | [7.7–17.9]| 14.8 (1.8) |       |
| Age, males (years)            | [9.3–17.6]| 13.6 (2.2) | ≤ 0.001|
| Doses in mg.                  |           |           |       |
| Start dose (Mean)             |           |           |       |
| Sertraline                    | 12.5–50 (27.3) | 25–200 (105.3) | 25–200 (110.0) |
| Fluoxetine                    | 10–20 (10.9) | 10–40 (25.4) | 10–40 (26.7) |
| Citalopram                    | 10        | 10        | 20    |

**Comparison of age groups.** Pearson’s Chi-square test was used to test for significance.

**Comparison of mean age by sex.** Mann–Whitney $U$ test was used to test for significance.

**Fig. 2** Psychiatric diagnoses in the study population. Most patients, 71.5% ($n = 261$), had more than one diagnosis on initiation accordingly; the number of diagnoses are higher than the number of patients included in the study. If a patient had more than one diagnosis from the same diagnosis group, it was counted only once in this figure. Depression, pervasive developmental disorders, anxiety, and OCD were the most abundant diagnoses. The insert square depicts the types of depression.
either the patient or the parent(s) was informed specifically about suicidality as an adverse effect of SSRI.

Patients with depression as indication for SSRI treatment were more likely to receive information specifically about risk of suicidality compared to patients with other diagnostic indications (34.7%, n = 51 vs. 19.7%, n = 43, p = 0.001).

There was no difference between the level of information given to the patient or their parent(s) according to the patient admission status. However, outpatients or their parent(s) were more likely to receive information specifically about suicidality as an adverse effect of SSRIs than inpatients or their parent(s) (28.9%, n = 82 vs. 14.8%, n = 12, p = 0.007).

Patients who had displayed suicidality prior to SSRI initiation or their parent(s) were more likely to receive information from the clinicians regarding adverse effects than patients with no previous suicidality (86.2%, n = 218 vs. 71.4%, n = 80, p = 0.001). Likewise, clinicians were more likely to inform specifically about the risk of suicidality to patients or the parent(s) of patients with previous suicidality (28.9%, n = 73 vs. 18.8%, n = 21, p = 0.042).

Patients or the parent(s) of patients who were initiated on SSRIs before the issue of the 2013 version of the guidelines from the Danish Health Authority were less likely to receive information from the clinicians about adverse effects (68.9%, n = 42 vs. 84.2%, n = 256, p = 0.005), but there was no statistically significant difference (p = 0.131) between the level of information specifically about the risk of suicidality before and after the issue of the 2013 version of the guidelines.

There was no significant difference between the level of information given to the patient or their parent(s) according to age group (p = 1.57); gender (p = 2.64) or indication (p = 0.368) and no significant difference between information specifically about suicidality given to the patient or their parent(s) according to age group (p = 0.134) or gender (p = 0.263).

**Monitoring for suicidality**

Table 3 shows that the majority (83.3%, n = 304) of patients were monitored for suicidality in the period after SSRI initiation. Within the first 4 and 6 weeks after SSRI initiation, respectively, 59.7% (n = 218) and 67.7% (n = 247) of the patients were monitored for suicidality. When SSRIs was initiated, 51.0% (n = 186) of patients were monitored for suicidality.

Children were less likely to be monitored for suicidality after SSRI initiation than adolescents (69.8%, n = 90 vs. 90.7%, n = 214, p < 0.001) and this finding was consistent within the first four weeks (43.4%, n = 56 vs. 68.6%, n = 162, p < 0.001), and the first 6 weeks (49.6%, n = 64 vs. 77.5%, n = 183, p < 0.001). Inpatients were more likely to be monitored for suicidality than outpatients (95.1%, n = 77 vs. 79.9%, n = 227, p = 0.001), within 4 weeks (79.0%, n = 64 vs. 54.2%, n = 154, p < 0.001) and within 6 weeks (85.2%, n = 69 vs. 62.7%, n = 178, p < 0.001). Patients with an indication of depression were more likely to be monitored for suicidality compared to patients with other indication diagnoses (93.9%, n = 138 vs. 76.1%, n = 166, p < 0.001).

Patients with an indication of OCD were less likely to be monitored for suicidality than patients with other diagnostic indications (71.3%, n = 62 vs. 87.1%, n = 242, p = 0.001), but this relationship was not significant when stratified for age (children: p = 0.081, adolescents: p = 0.347). Patients with previous suicidality were more likely to be monitored compared to patients with no previous suicidality in the period after SSRI initiation (67.9%, n = 76 vs. 90.1%, n = 228, p < 0.001), within the first 4 weeks after SSRI initiation (38.4%, n = 43 vs. 69.2%, N = 175, p < 0.001) and the first 6 weeks (47.3%, n = 53 vs. 76.7%, n = 194, p < 0.001).

Patients where SSRIs was initiated before the issue of the 2013 guidelines from the Danish Health Authority were less likely to be monitored (63.9%, n = 39 vs. 87.2%, n = 265, p < 0.001) within the first 4 weeks (36.1%, n = 22 vs. 64.5%, n = 196, p < 0.001) and the first 6 weeks (44.3%, n = 27 vs. 72.4%, n = 220, p < 0.001).

Logistic regression analyses were performed with, respectively, any monitoring during the observation period; monitoring within 4 weeks; and monitoring within 6 weeks after SSRI initiation as the dependent variable and age; gender; admission status; indication and previous suicidality as predictor variables. Table 4 gives the odds ratios (ORs) and the probability values for each of the predictor values. This shows that both increasing age, inpatient status, an indicating diagnosis of depression for SSRI, and previous suicidality increase the probability of monitoring for suicidality after SSRI initiation.
20.3% (n = 4) of the patients with a diagnosis of severe depression (n = 20) received no non-pharmacological intervention prior to SSRI initiation, but a diagnosis of severe depression and no prior non-pharmacological interventions (p = 0.103) were not related.

After SSRI initiation, 93.4% (n = 341) of patients were treated with a non-pharmacological intervention in parallel with SSRIs. 60.3% (n = 220) of patients were treated with psychotherapy, 46.8% (n = 171) were treated with supportive consultations, and 79.7% (n = 126) were treated with psychoeducation. All inpatients (100%, n = 81) received non-pharmacological interventions, whereas 91.5% (n = 260) of outpatients received non-pharmacological interventions in parallel with SSRIs (p = 0.007). Patients who were initiated on SSRIs before the issue of the 2013 version of the guidelines from the Danish Health Authority were less likely to receive non-pharmacological treatment

### Table 3 Monitoring for suicidality after SSRI initiation

|                | No. of patients | %       | p     |
|----------------|-----------------|---------|-------|
| Not monitored  | 61              | 16.70%  |       |
| Monitored      | 304             | 83.30%  |       |
| Children       | 90              | 69.80%  |       |
| Adolescents    | 214             | 90.70%  | 0.000 |
| Monitored first 4 weeks | 218          | 59.70%  |       |
| Children       | 56              | 43.40%  |       |
| Adolescents    | 162             | 68.60%  | 0.000 |
| Monitored first 6 weeks | 247          | 67.70%  |       |
| Children       | 64              | 49.60%  |       |
| Adolescents    | 183             | 77.50%  | 0.000 |

### Method for monitoring

- **Face-to-face**: 269 (88.5%)<sup>a</sup>
- **Telephone**: 4 (1.3%)<sup>a</sup>
- **Face-to-face and telephone**: 27 (8.9%)<sup>a</sup>
- **Unknown**: 4 (1.3%)<sup>a</sup>

### Use of side-effect rating scale<sup>b</sup>

- **Monitored at SSRI initiation**: 186 (51.00%)<sup>0.000</sup>
- **Children**: 46 (35.70%)
- **Adolescents**: 140 (59.30%)

### Monitored with side-effect rating scale at SSRI initiation

- **Children**: 56 (43.40%)<sup>a</sup>
- **Adolescents**: 162 (68.60%)<sup>a</sup>

### Pearson's Chi-square test

- **No. of patients %**
  - Not monitored 61 16.70%
  - Monitored 304 83.30%
  - Children 21 69.80%
  - Adolescents 214 90.70%
  - Monitored first 4 weeks 218 59.70%
  - Children 56 43.40%
  - Adolescents 162 68.60%
  - Monitored first 6 weeks 247 67.70%
  - Children 64 49.60%
  - Adolescents 183 77.50%

**SSRI** selective serotonin reuptake inhibitor

<sup>a</sup>Percentage of patients monitored

<sup>b</sup>UKU side-effect rating scale or unspecified side-effect rating scale

<sup>c</sup>Percentage of patients monitored at SSRI initiation

*Pearson's Chi-square test was used to test for significance*

### Non-pharmacological interventions

Before SSRI treatment was initiated, 89.3% (n = 326) of patients were treated with a non-pharmacological intervention. 57.3% (n = 209) of patients were treated with psychotherapy, 38.6% (n = 141) were treated with supportive consultations, and 27.9% (n = 102) were treated with psychoeducation. Almost all inpatients (97.5%, n = 79) received non-pharmacological interventions prior to SSRI initiation, whereas a significantly lower proportion of outpatients were treated with non-pharmacological interventions prior to SSRIs (87.9%, p = 0.004). There was no difference between the extent of non-pharmacological interventions prior to SSRI initiation according to age group (p = 111), gender (p = 484), indication for SSRIs (p = 0.388), previous suicidality (p = 0.722), or the SSRI initiation date (p = 0.363).
in parallel with SSRIs (86.9%, n = 53 vs. 94.7%, n = 288, p = 0.024). There was no difference between the extent of non-pharmacological interventions after SSRI initiation according to age group: (p = 0.276), gender: (p = 0.513), indication (p = 0.401), and previous suicidality (p = 0.096).

To account for misclassification of psychotherapy for supportive consultations, the number of patients treated with either/or was calculated. Thus, the percentage of patients who were treated with psychotherapy or supportive consultations was 73.7% (n = 269) prior to and 79.7% (n = 291) in parallel with SSRI treatment (Table 5).

Discussion

In this study of SSRI-treated children and adolescents in a large Danish hospital setting, the clinical guidelines regarding information to patients or their parents, monitoring for suicidality, and use of non-pharmacological interventions were followed in the majority of cases. Yet, some patients were not managed according to guidelines and the clinical management of SSRI-related suicidality differed depending on patient age, admission status, indication for SSRI treatment, date of SSRI initiation, and whether the patient had displayed suicidality prior to SSRI initiation.

Pre-consent information about suicidality as an adverse effect of SSRI

The majority of patients or their parent(s) were informed about adverse effects of SSRIs before treatment initiation. However, less than a quarter of the parents were informed specifically about suicidality. This finding seems alarming and violates the clinical recommendation that parent(s) should be instructed in how to support the monitoring for suicidality [11]. However, because of the study design, information is limited on what is exactly covered in the term “general information” about adverse effects. Presumably, general information given about adverse effects covers suicidality. In this study, for the majority of cases, the parent(s) notified about suicidality with or without SSRIs.
were informed generally about adverse effects. Accordingly, if the presumption is true, information about adverse effects from the healthcare providers to patients and their parent(s) was in compliance with recommendations in the majority of cases. On the other hand, patients who were treated with SSRIs for depression, and patients with previous suicidality and outpatients were significantly more likely to receive information specifically about the risk of suicidality. Thus, for these patient groups, the clinicians find it important to emphasize the risk of suicidality as an adverse effect. The clinical guidelines deviate on how to handle SSRI-related suicidality after SSRI initiation and 67.7% of patients were monitored for suicidality at SSRI initiation. Register –

Monitoring for suicidality

The majority (83.3%) of patients were monitored for suicidality after SSRI initiation and 67.7% of patients were monitored within 4–6 weeks after SSRI initiation, as specified by the clinical guidelines from The Danish Health Authority. Busch et al. [30] assessed changes in monitoring of patients treated with antidepressants after FDA warnings in the USA. Monitoring was defined as at least two outpatient visits within 30 days of initial drug treatment. In the study, 28–30% of the children were monitored after initial drug treatment. Comparatively, the patients in the present study were more intensely monitored.

Patients who were treated with SSRIs for depression were more likely to be monitored for suicidality than patients who were treated with SSRIs for other diagnostic indications. Since suicidal ideation and behaviour are typical clinical manifestations of depression, patients with depression or depressive symptoms are routinely monitored throughout their illness for suicidality in the clinic which might explain this difference. However, as noted above, symptoms of suicidality are not restricted to depressive disorders, and little is known about other risk factors for SSRI-related suicidality [27–29]. One well-established risk factor for suicide in general is previous suicidality. Patients with suicidality prior to SSRI initiation were more likely to be monitored for suicidality after SSRI initiation than patients who had not been suicidal before. This suggests heightened clinician alertness for these patients as well as common clinical practice of routine monitoring when there is a history of suicidality.

In the present study, younger age was a risk factor for failure to monitor for suicidality. This finding might reflect an assumption that suicidality is unlikely in younger children. Historically, children were believed not to be able to exhibit suicidality [31]. Today, the literature illustrates that children can commit suicide, attempt suicide, and have suicidal ideations as early as preschool age [31]. Meta-analyses evaluating SSRI-related suicidality have not separated data for children and adolescents. As a result, it is unknown if SSRI-related suicidality differs between children and adolescents. Government warnings as well as clinical guidelines do not clearly distinguish between monitoring children and adolescents during SSRI treatment.

SSRI initiation before 2013 was a risk factor for less monitoring. The observed difference implies a delay in the implementation of new knowledge, since the guidelines from The Danish Health Authority from 2007, 2012 and 2013 all emphasize monitoring for suicidality after SSRI initiation [11, 21].

Just more than half of the patients in the present study were monitored for suicidality at SSRI initiation. Registering baseline suicidality when initiating SSRI treatment is not specifically recommended in the clinical guidelines from The Danish Health Authority. On the other hand, it is good clinical practice to monitor symptoms that may later occur as side effects before initiating medical treatment [13].

Non-pharmacological interventions

The greatest part of patients in this study received non-pharmacological interventions for a broad range of indications both prior to and in parallel with SSRI treatment. In this study, all but two inpatients received non-pharmacological interventions prior to, and all inpatients were treated with non-pharmacological interventions in parallel with SSRI treatment. Since hospitalization, both acute and planned, was registered as a non-pharmacological intervention, this finding is evident. There were no other significant predictors for not providing non-pharmacological interventions. Contrary to other diagnoses, for severe depression, combination treatment can be considered as first-line treatment according to recommendations [11]. Thus, patients with this diagnosis were expected to be less likely to receive
non-pharmacological interventions alone prior to SSRI treatment, but no relationship between a diagnosis of severe depression and absence of non-pharmacological interventions prior to SSRI treatment was found.

**Study strengths and limitations**

The strength of this study was the systematic extraction of data from digitalised prescription and medical record software for a large number of patients in a public hospital service in the most populous region of Denmark. The method of retrieving data from the clinical database ensured a maximal entry of eligible participants. Data were extracted on patient level, which allowed for detailed clinical data on treatment with SSRIs. By extracting data directly from the digitalised software, recall bias and non-response were avoided. Our findings are by large generalizable to the whole population of SSRI-treated children in Denmark, due to the Danish health authorities limiting prescriptions of any psychopharmacological drug to be handled by specialists in child and adolescent psychiatry, i.e., general practitioners must refer children and adolescents in need for psychiatric drug treatment to the specialist treatment. The majority of these specialists are affiliated with the hospital CAMHS clinics. In 2016, 65.7% of first prescriptions for antidepressants for children and adolescents were prescribed by doctors affiliated with hospital clinics, and 80.9% of children and adolescents with a psychiatric diagnosis had at least one hospital contact in 2016 [32]. Furthermore, the CAMHS in Copenhagen is the largest in the country, and all other CAMHS have similar diagnostic patient distributions, and follow the same national guidelines. It cannot, however, be concluded that all CAMHS have exactly the same adherence to national guidelines as the CAMHS Copenhagen.

The main limitations of this study are information bias and the risk of misclassification. Healthcare providers in Denmark are liable [33] to record information about patients’ conditions, treatment, and information given from healthcare providers to the patient. Nevertheless, information bias might occur, because the medical record is not a meticulous report of the consultation and because of limited information on the use of non-pharmacological interventions outside of CAMHS (i.e., the social services, private sector, and school counsellors). Documentation in the medical journal is a limited way to measure information about adverse effects, since it is unknown to what degree the information is understood by patient or their parent(s). In this study, the focus is rather on the clinicians’ awareness to recommendations.

To account for the risk of misclassification, the extraction of data was restricted to only two researchers, and doubts were solved in a standardized way. As an example, if in doubt whether an event was in the category “supportive consultations” or “psychotherapy”, the event was systematically classified as “supportive consultations”.

It could have been interesting to collect data on the type of treatment facility within the CAMHS and which healthcare providers treated the patients. Specific healthcare providers might be less likely to comply with clinical guidelines than others, thus interfering with the results of this study.

**Conclusion**

The present study aimed to determine whether daily clinical practice complied with specific recommendations using data from digitalized prescription software and digitalized medical records. The study method emphasizes the feasibility of monitoring clinical practice by digitalized data.

The study found some deviances from recommendations concerning the management of suicidality when treating youth with SSRIs. Of important clinical relevance was the observation that patients of younger age and/or with diagnostic indications for SSRI treatment other than depression were less likely to be managed according to recommendations. Patients at risk, i.e., with previous suicidality, were more likely to be managed according to recommendations. Clinicians were less likely to inform about adverse effects and monitor for suicidality when SSRI initiation was before 2013. This stresses the responsibility of authorities in issuing prompt recommendations as early as possible, as it has potential of affecting clinical practice.

These findings have implications for improving clinical practice, i.e., it might be considered that clinical guidelines highlight the need for clinicians to increase awareness on suicidality when treating youth with SSRIs regardless of patient age and diagnosis. Furthermore, our findings emphasize the need for future research in SSRI-related suicidality to identify subgroups at risk and specific time-periods for increased risk of suicidality during SSRI treatment. Until these issues are clarified, assessment and pre-consent information of suicidality are necessary as a precautionary measure for all children and adolescents treated with SSRIs. Clinicians should be cautious when treating patients at younger age and patients with another indication for SSRI treatment than depression, since these subgroups are less likely to be informed about and monitored for suicidality.

**Compliance with ethical standards**

**Conflict of interest** The authors state that they have no conflicts of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Bachmann CJ et al (2016) Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacol 26(3):411–419
2. Pottegard A et al (2014) Use of SSRIs among Danish children: a nationwide study. Eur Child Adolesc Psychiatry 23(12):1211–1218
3. Sharma T et al (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 352:i65
4. Gordon MS, Melvin GA (2014) Do antidepressants cause children and adolescents suicidal? J Paediatr Child Health 50(11):847–854
5. Bridge JA et al (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297(15):1683–1696
6. Kaizar EE et al (2006) Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials 3(2):73–90 (discussion 91–98)
7. Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63(3):332–339
8. FDA (2004) Suicidality in children and adolescents being treated with antidepressant medications. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm161679.htm
9. FDA (2007) Antidepressant use in children, adolescents, and adults. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm
10. EMA (2005) European medicines agency finalises review of antidepressants in children and adolescents. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/12/news_detail_000882.jsp&mid=WC0b01ac058004d5c1
11. Vejledning om medikamentel behandling af børn og unge med psykiske lidelser (2013) Available from: https://www.retsinformation.dk/pdfPrint.aspx?id=146409
12. Cheung AH et al (2007) Guidelines for adolescent depression in primary care (GLAD-PC): II treatment and ongoing management. Pediatrics 120(5):e1313–e1326
13. Lawton A, Moghary OS (2016) Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline CG28). Arch Dis Child Educ Pract Ed 101(4):206–209
14. NICE (2005) Clinical guideline: Obsessive-compulsive disorder and body dysmorphic disorder: treatment. nice.org.uk/guidance/cg31
15. Geller DA, March J, The AACAP Committee on Quality Issues (CQI) (2012) Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 51(1):98–113
16. Connolly SD (2007) Bernstein GAI (2007) Work Group on Quality, Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 46(2):267–283
17. Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292(3):338–343
18. Simon GE et al (2006) Suicide risk during antidepressant treatment. Am J Psychiatry 163(1):41–47
19. Valuck RJ, Orton HD, Libby AM (2009) Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry 70(8):1069–1077
20. Hetrick SE et al (2012) Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 11:CD004851
21. Sundhedsstyrelsen, Vejledning om medikamentel behandling af børn og unge med psykiske lidelser VEJ nr 10332 af 10/12/2007. 2007
22. Statistik D. Statistikbanken. http://www.statistikbanken.dk/statbank/default.asp?w=1366
23. WHO (1990) International statistical classification of diseases and related health problems (ICD-10). 10th ed. World Health Organization, Geneva
24. Posner K et al (2007) Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164(7):1035–1043
25. Sorensen MJ et al (2011) Landsdækkende klinisk retningslinje vedrørende udredning og behandling af depression hos børn og unge. http://www.bupenet.dk/media/Landsdekkende_klinisk_retningslinje_vedr%C3%B8rende.pdf
26. Becker Nissen J et al. Landsdækkende klinisk retningslinje vedrørende udredning og behandling af Obsessiv-kompulsiv tilstand (OCD) hos børn og unge. http://www.bupenet.dk/media/retningslinjerOCD_arbejdsgruppe_revideret_vers.pdf
27. Mortensen PB et al (2000) Psychiatric illness and risk factors for suicide in Denmark. Lancet 355(9197):9–12
28. Storch EA et al (2015) Frequency and correlates of suicidal ideation in pediatric obsessive-compulsive disorder. Child Psychiatry Hum Dev 46(1):75–83
29. Kuba T et al (2011) Suicide-related events among child and adolescent patients during short-term antidepressant therapy. Psychiatry Clin Neurosci 65(3):239–245
30. Busch SH et al (2010) Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv 61(1):11–16
31. Tishler CL, Reiss NS, Rhodes AR (2007) Suicidal behavior in children younger than twelve: a diagnostic challenge for emergency department personnel. Acad Emerg Med 14(9):810–818
32. Færre starter i behandling med antidepressiv medicin. 2017, Sundhedsdatastyrelsen, The Danish Health Data Authority
33. Bekendtgørelse om autoriserede sundhedspersoners patientjournaler (journalføring, opbevaring, videregivelse og overdragelse m.v.). 2016, Styrelsen for Patientsikkerhed

 Springer